



King's Research Portal

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Patel, R., Wilson, R., Jackson, R. G., Ball, M., Shetty, H., Broadbent, M., Stewart, R. J., McGuire, P., & Bhattacharyya, S. (in press). Impact of cannabis use on clinical outcomes and treatment failure in first episode psychosis. *NPJ SCHIZOPHRENIA*, 2, M111. Article 16008.

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

associated with remission status at follow-up. Substance use in the year after psychosis onset was associated with increased probability of poor medication adherence during the follow-up. In particular, the analysis showed significant main effects of nicotine dependence (OR=2.18), cannabis use (OR=2.86), and stimulant use (OR=2.63) on the odds of being non-adherent to treatment. In contrast, the OR failed to reach significance for an association between problem drinking and poor medication adherence.

Substance use in the first year after psychosis onset was associated with increased probability of non-remission during the one year follow-up. In particular, the analysis showed significant main effects of nicotine dependence (OR=2.13) and cannabis use (OR=2.60) on probability of not achieving remission. In contrast, the ORs failed to reach significance for an association between problem drinking and non-remission as well as between stimulant use and non-remission. Medication adherence significantly predicted remission during the one year follow-up. In particular, patients with poor medication adherence showed a six-fold increased probability of non-remission of their psychosis when compared with patients with good medication adherence. When substance use in the one year follow-up period was added in to this model, the association between medication adherence and remission was still significant. Following Baron and Kenny's approach to mediation, criteria were satisfied only for nicotine dependence and cannabis use post onset. In order to test for mediation, the associations between nicotine dependence after psychosis onset and non-remission as well as between cannabis use and non-remission were adjusted for medication adherence. When medication adherence was added in to the model, even if increased, the ORs failed to reach significance. Sobel tests for mediation showed that medication adherence was a significant mediator of the relationship between nicotine dependence and remission ($z=2.02$, $P=0.04$) as well as that between cannabis use and remission ($z=2.12$, $P=0.03$).

Discussion: In conclusion, medication adherence lies on the causal pathway between nicotine dependence and cannabis on the one hand and non-remission on the other. As cannabis and tobacco are often consumed together in the same joint and there is accumulating evidence of a common underlying vulnerability to both substances, further research is needed to definitively disentangle their independent contribution on patients' clinical outcome.

M110. 36 Month results of a smoking and healthy lifestyles intervention among people with a psychotic disorder

Amanda Baker^{*1}, Robyn Richmond², Frances Kay-Lambkin¹, Sacha Folia³, David Castle⁴, Robin Callister¹, Jill Williams⁵, Vanessa Clark¹, Terry Lewin⁶, Kerrin Palazzi¹

¹University of Newcastle, Australia, ²University of NSW, Australia, ³Monash University, Australia, ⁴University of Melbourne, Melbourne, Victoria, Australia, ⁵Robert Wood Johnson Medical School, ⁶Hunter New England Mental Health, Australia

Background: People with schizophrenia have a life expectancy 15 years less than the general community, and much higher rates of chronic diseases such as cardiovascular disease, diabetes and obesity. In response to this disproportionately high burden of illness the first Australian National Report Card on Mental Health stated "the reduced life expectancies and poor health of people with the most severe mental illnesses...is a national disgrace and it should be a major public health concern". Telephone interventions for health behaviors (such as smoking, alcohol use, low fruit and vegetable consumption and high levels of sedentary activity) as well as for psychotic symptomatology and also smartphone applications have been evaluated with promising results. This is the first randomized controlled trial to evaluate a cognitive-behavioral intervention addressing smoking and other health behaviors among people with psychotic disorders.

Methods: Study participants were randomly assigned to receive a single face to face session consisting of feedback and motivational interviewing and nicotine replacement therapy, plus either: (i) a face-to-face intervention targeting multiple health risk behaviors; or (ii) a predominantly telephone delivered intervention involving monitoring. Follow-up surveys were completed at 15 weeks ($n=165$, 70.2%),

12 months ($n=139$, 59%), 18 months ($n=132$, 56.2%), 24 months ($n=133$, 56.6%), 30 months ($n=129$, 54.9%) and 36 months ($n=134$, 57%). ITT analysis was used for primary outcomes and mixed models were used for both primary and secondary modeling, so all study participants were included in analyses.

Results: At baseline, participants ($N=235$, Age, $M=41.6$ years, 59% male) were smoking on average 28.6 (SD= 15.3) CPD. There were no significant overall differences between the telephone and face-to-face conditions in the primary smoking outcome of biochemically confirmed point-prevalence abstinence rates (8% and 11% respectively) at 36 months. There were no significant differences between groups in most measures of exercise, diet and body measures (total minutes walking per week, total minutes sitting per week, BMI, waist circumference, weight, waist-to-hip ratios).

Discussion: Face-to-face and telephone-delivered interventions are feasible and effective among people with severe mental disorders for smoking. Interventions for multiple health behavior change appear worthy of further research among people with psychotic disorders.

M111. Impact of cannabis use on clinical outcomes and treatment failure in first episode psychosis

Rashmi Patel^{*1}, Robin Wilson¹, Richard Jackson¹, Michael Ball¹, Hitesh Shetty², Matthew Broadbent², Robert Stewart¹, Philip McGuire¹, Sagnik Bhattacharyya¹

¹IoPPN, King's College London, London, UK, ²BRC Nucleus, South London and Maudsley NHS Foundation Trust, Beckenham, UK

Background: Cannabis is frequently used by people with first episode psychosis (FEP), though its effect on clinical outcome is less clear. We investigated whether cannabis use may be associated with increased risk of hospitalization and whether antipsychotic treatment failure, as indexed by number of unique antipsychotics prescribed, may mediate this effect in a large dataset of patients with FEP.

Methods: Data were obtained from electronic health records of 2,026 people with FEP in the South London and Maudsley NHS Foundation Trust (SLaM) using the Clinical Record Interactive Search tool (CRIS). Cannabis use was identified using natural language processing. Data on subsequent hospital admission and the number of unique antipsychotics prescribed (a marker of treatment failure) were obtained and analyzed using multivariable regression and mediation analyses with age, gender, ethnicity, marital status and diagnosis as covariates.

Results: Cannabis use was present in 46.3% of the sample at first presentation and was particularly common in patients who were 16-25, male and single. It was associated with increased frequency of hospital admission (incidence rate ratio 1.50, 95% CI 1.25 to 1.80), increased likelihood of compulsory admission (odds ratio 1.55, 1.16 to 2.08) and greater number of inpatient days (B coefficient 35.1 days, 12.1 to 58.1). Antipsychotic treatment failure mediated increased frequency of hospital admission (natural indirect effect: 1.09, 95% CI 1.01 to 1.18; total effect: 1.50, 1.21 to 1.87), increased likelihood of compulsory admission (NIE: 1.27, 1.03 to 1.58; TE: 1.76, 0.81 to 3.84) and greater number of inpatient days (NIE: 17.9, 2.4 to 33.4; TE: 34.8, 11.6 to 58.1).

Discussion: Cannabis use in patients with FEP was associated with increased likelihood and duration of hospital admission. This was linked to the prescription of several different antipsychotic drugs, indicating clinical judgement of antipsychotic treatment failure. This suggests that cannabis use might be associated with worse clinical outcomes in psychosis by contributing towards failure of antipsychotic treatment.

M112. Better social but worse academic premorbid adjustment in cannabis-users psychotic patients across Europe

Laura Ferraro¹, Capuccio Veronica¹, Caterina La Cascia¹, Lucia Sideli¹, Alice Mulè¹, Fabio Seminerio^{*1}, Crocettarachele Sartorio¹, Giada Tripoli¹, Robin Murray², Daniele La Barbera¹, Marta Di Forti²

¹University of Palermo, ²Institute of Psychiatry, King's College

Background: Several studies report that patients with psychosis who used cannabis have a better cognitive performance than those who